Recent Advances and Perspectives in Cancer Drug Design
| Autor: | Luma G. Magalhães, Adriano D. Andricopulo, Leonardo L. G. Ferreira |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Drug medicine.medical_specialty Biomedical Research media_common.quotation_subject medicine.medical_treatment Antineoplastic Agents Disease QUÍMICA MÉDICA cytotoxic therapy drug discovery Targeted therapy Business process discovery 03 medical and health sciences 0302 clinical medicine medicine Humans lcsh:Science Intensive care medicine Cancer media_common Pharmaceutical industry Clinical Trials as Topic Multidisciplinary business.industry Drug discovery targeted therapy medicine.disease Clinical trial 030104 developmental biology Drug Design 030220 oncology & carcinogenesis lcsh:Q business |
| Zdroj: | Anais da Academia Brasileira de Ciências, Vol 90, Iss 1 suppl 2, Pp 1233-1250 (2018) Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual) Universidade de São Paulo (USP) instacron:USP Anais da Academia Brasileira de Ciências v.90 n.1 suppl.2 2018 Anais da Academia Brasileira de Ciências Academia Brasileira de Ciências (ABC) instacron:ABC Anais da Academia Brasileira de Ciências, Issue: ahead, Published: 14 MAY 2018 Anais da Academia Brasileira de Ciências, Volume: 90, Issue: 1 Supplement 2, Pages: 1233-1250, Published: 14 MAY 2018 |
| ISSN: | 1678-2690 0001-3765 |
| Popis: | Cancer is one of the leading causes of death worldwide. With the increase in life expectancy, the number of cancer cases has reached unprecedented levels. In this scenario, the pharmaceutical industry has made significant investments in this therapeutic area. Despite these efforts, cancer drug research remains a remarkably challenging field, and therapeutic innovations have not yet achieved expected clinical results. However, the physiopathology of the disease is now better understood, and the discovery of novel molecular targets has refreshed the expectations of developing improved treatments. Several noteworthy advances have been made, among which the development of targeted therapies is the most significant. Monoclonal antibodies and antibody-small molecule conjugates have emerged as a worthwhile approach to improve drug selectivity and reduce adverse effects, which are the main challenges in cancer drug discovery. This review will examine the current panorama of drug research and development (R&D) with emphasis on some of the major advances brought to clinical trials and to the market in the past five years. Breakthrough discoveries will be highlighted along with the medicinal chemistry strategies used throughout the discovery process. In addition, this review will provide perspectives and updates on the discovery of novel molecular targets as well as drugs with innovative mechanisms of action. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|